[The Fly] JPMorgan believes Pfizer Inc. (NYSE:PFE) is less likely to re-engage with AstraZeneca (AZN) after entering into an agreement to co-develop and co-commercialize MSB0010718C, Merck KGaA’s (MKGAY) anti-PDL1 antibody. The firm thinks the transaction “significantly improves” Pfizer’s position in the I/O space. It keeps an Overweight rating on Pfizer with a $35 price target.
In other news, Pfizer announced that TRUMENBA, the first and only FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age, is now available for order by healthcare providers in the United States.
Taking a look at the company’s recent performance, Pfizer Inc (PFE) reported Third quarter earnings for fiscal 2014 on October 28TH. The company reported actual earnings per share of $0.57 against the consensus Street estimate of $0.55. Pfizer Inc (PFE) posted revenue of $12.40 billion against estimates of $12.24 billion.
There are currently fifteen analysts that we track that cover the stock. Of those fifteen, eight have a Buy rating and seven have a Hold rating. On a consensus basis this yields a score of 2.53 and a Buy. The combined price objective of these covering analysts is $33.66, which represents a 12.81% upside difference to the last closing price.
A recent analyst activity consisted of Jefferies Group Reiterating their buy stance on the company. Jefferies Group has a price target from $38.00 to $40.00 which represents an upside of 34.05% from the last closing price. On the date of the report, the stock closed at $28.47.
Another research firm weighing in recently was Deutsche Bank who initiated coverage on the stock. On August 27th Deutsche Bank upgraded their price target on the stock from $34.00, or a 13.94% upside to the current price. On the day of the report, PFE shares closed at $29.49.
Pfizer Inc. (NYSE:PFE) develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. The company’s Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimer’s disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation. Its Specialty Care and Oncology segment provides prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses.